Nevertheless, our findings underscore the need to balance a reciprocal upregulation of NR4A3 and NFAT signaling in the setting of PRDM1 deficiency to generate effective CAR T-cell-mediated responses in a variety of tumor types. This evidence concerns the gene PRDM1 and neoplasm.